Laurence Patterson, PhD
Medicinal Chemistry Advisor
Dr. Laurence Patterson is professor emeritus of drug discovery with over 30 years’ experience of research in UK academia starting at DeMontfort University, then University College London School of Pharmacy and latterly Director of the Institute of Cancer Therapeutics (ICT), University of Bradford. He gained his PhD from the Chelsea Department of Pharmacy, Kings College, London and is an elected honorary member of the Royal Pharmaceutical Society of Great Britain. He has published over 200 papers and patents concerned with the discovery and development of new drugs, formulations and cell imaging reagents.
Prof Patterson is responsible for the discovery of Banoxantrone (AQ4N), a tumor hypoxia activated agent in Phase 1/II trials by OncoTherics Ltd and has led the team that developed MMP-activated vascular disrupting agents and CYP-activated ultrapotent cytotoxin prodrugs
now licensed to InCanThera Ltd a spinout company of the ICT, University of Bradford that he founded. He is also a founding director of Biostatus Ltd which has developed and marketed novel solutions for imaging, cytometry and drug screening since 2003 and was awarded the 2012 Team Innovation medal from the Royal Society of Chemistry. He is also shareholder and chair of SAB for several start-ups including OncoTherics Ltd, BioTherics Ltd and Biosuspensions Ltd and is a visiting Professor to the Shanghai Institute of Materia Medica, CAS.
